114 related articles for article (PubMed ID: 12439862)
21. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
Schaefer G; Fitzpatrick VD; Sliwkowski MX
Oncogene; 1997 Sep; 15(12):1385-94. PubMed ID: 9333014
[TBL] [Abstract][Full Text] [Related]
22. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
23. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
24. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
26. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
27. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
Hutcheson IR; Goddard L; Barrow D; McClelland RA; Francies HE; Knowlden JM; Nicholson RI; Gee JM
Breast Cancer Res; 2011 Mar; 13(2):R29. PubMed ID: 21396094
[TBL] [Abstract][Full Text] [Related]
28. TCDD elevates erbB2 expression and signaling in T47D cells by reversing serum potentiation of estrogen receptor activity, independent of estrogen levels and enhanced ER down-regulation.
Angus WG; Campaigne Larsen M; Jefcoate CR
Mol Cell Endocrinol; 2000 Dec; 170(1-2):1-13. PubMed ID: 11162886
[TBL] [Abstract][Full Text] [Related]
29. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
30. Changes in heregulin beta1 (HRGbeta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line.
Yoo JY; Hamburger AW
Mol Cell Endocrinol; 1998 Mar; 138(1-2):163-71. PubMed ID: 9685225
[TBL] [Abstract][Full Text] [Related]
31. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
32. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
Xia W; Liu LH; Ho P; Spector NL
Oncogene; 2004 Jan; 23(3):646-53. PubMed ID: 14737100
[TBL] [Abstract][Full Text] [Related]
33. Expression and differential signaling of heregulins in pancreatic cancer cells.
Kolb A; Kleeff J; Arnold N; Giese NA; Giese T; Korc M; Friess H
Int J Cancer; 2007 Feb; 120(3):514-23. PubMed ID: 17096356
[TBL] [Abstract][Full Text] [Related]
34. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer.
Yonezawa M; Wada K; Tatsuguchi A; Akamatsu T; Gudis K; Seo T; Mitsui K; Nagata K; Tanaka S; Fujimori S; Sakamoto C
Digestion; 2009; 80(4):215-25. PubMed ID: 19797898
[TBL] [Abstract][Full Text] [Related]
35. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.
Hijazi MM; Thompson EW; Tang C; Coopman P; Torri JA; Yang D; Mueller SC; Lupu R
Int J Oncol; 2000 Oct; 17(4):629-41. PubMed ID: 10995872
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.
Xiong S; Grijalva R; Zhang L; Nguyen NT; Pisters PW; Pollock RE; Yu D
Cancer Res; 2001 Feb; 61(4):1727-32. PubMed ID: 11245489
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
[TBL] [Abstract][Full Text] [Related]
38. ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells.
Keely SJ; Barrett KE
J Biol Chem; 1999 Nov; 274(47):33449-54. PubMed ID: 10559227
[TBL] [Abstract][Full Text] [Related]
39. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
40. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines.
deFazio A; Chiew YE; Sini RL; Janes PW; Sutherland RL
Int J Cancer; 2000 Aug; 87(4):487-98. PubMed ID: 10918187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
